Q-omics provides the consensus-scored RERE profile across patient tissues and cancer cell-line models. RERE expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RERE is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RERE RNA expression shows 20,809 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where RERE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RERE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RERE survival associations across molecular data types. RERE RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RERE RNA expression–survival associations across cancer types. High RERE expression shows unfavorable associations in ACC and LIHC, but favorable associations in KIRC, LUAD, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RERE RNA expression.
This table summarizes RERE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RERE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RERE shows lower tumor expression in KICH, THCA, BRCA, BLCA and COAD and higher tumor expression in LIHC. The KICH box plot shows higher RERE RNA expression in normal versus tumor tissue (log2 FC = −1.229, t-test p < 0.001).
This table shows molecular features associated with RERE in patient tissues and cancer cell lines. In patient samples, RERE shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RERE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
